张坤罕见参与了港股打新。 3月6日张坤通过QDII中签1000股的蜜雪集团收盘大涨约15%，考虑到易方达亚洲精选QDII基金规模达36亿 元，若仅是打新策略，该股对张坤的超大型基金产品无法构成实质性业绩拉动，考虑到他本次参与港股打新亦 是一次罕见的操作，背后或是该基金布局消费的前奏。 与此同时，由于市场赚钱效应在多个行业扩散，张坤所管的易方达亚洲精选基金实际上也迎来了仓位结构平衡 的节点，此前该QDII几乎全部指向科网股并淡出大部分消费品重仓股，截至去年12月末，消费品公司在十大 股票中仅剩一只，而食品饮料行业更是近三年未曾出现在这只明星QDII重仓席位上，本次张坤首次以打新的 方式覆盖奶茶赛道，或许是他在消费品乃至食品饮料行业重新布局的思考，而企业的自由现金流或将成为引导 他在二级市场买入的关键。 中签蜜雪集团1000股 显然，在整个消费品赛道中，食品饮料几乎是导致消费基金经理业绩压力最大的品种之一，而张坤在上一次将 食品饮料赛道股票纳入前十大重仓股，正好还是三年前的2022年6月，当时在港股上市的蒙牛乳业为易方达亚 洲精选基金的第六大重仓股，但在2022年第三季度的报告中，蒙牛乳业已被张坤卖出，自此之后， ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $9.3 million, an 18% increase from $7.9 million in Q4 2023, and $37.7 million for the full year 2024, a 3% increase from $36.7 million in 2023 [25][34] - Adjusted to exclude revenue from a single large clinical solutions order of $2.7 million in 2023, total revenue growth was 11% in 2024 [9][25] - Free cash outflow improved from $26.7 million in 2023 to $13.5 million in 2024 [24][36] Business Line Data and Key Metrics Changes - Revenue from catalog reagents represented approximately 60% of total revenue, growing low single digits in 2024, with 7% growth in the second half of the year compared to the second half of 2023 [13] - Custom biopharma business grew about 40% in 2024, with a robust growth of approximately 25% excluding a new therapeutic customer [16] - Clinical Solutions revenue was $1.9 million in Q4 2024, a 110% increase from $0.9 million in Q4 2023, and $7.1 million for the full year 2024, a 5% increase from $6.7 million in 2023 [27] Market Data and Key Metrics Changes - Sales to biopharma customers represented approximately 70% of custom revenue and 25% of total revenue in 2024 [15] - The company supported 48 clinical customers in 2024, up from 34 in 2023, with 39 being biopharma-related [8][17] - The company expects mid-single-digit growth in catalog business for 2025, reflecting market stabilization [20] Company Strategy and Development Direction - The company aims to expand its product portfolio through collaborations and acquisitions over the next 12 to 24 months [22] - The focus remains on executing the growth strategy laid out in 2021 to achieve long-term sustainable growth [8] - The company plans to moderately increase investments in sales and marketing to position itself for market recovery [40] Management's Comments on Operating Environment and Future Outlook - Management noted cautiousness among customers due to macroeconomic uncertainty, particularly regarding capital flow into the sector [39] - The company expects 2025 to be a recovery year, with guidance for total revenue of $39 million to $42 million, implying 7% growth compared to 2024 [38] - Management expressed confidence in achieving at least 15% growth in custom products sold to biopharma accounts despite current uncertainties [21] Other Important Information - The company reported a net loss of $5.7 million for Q4 2024, an improvement from a net loss of $10.7 million in Q4 2023 [34] - Adjusted EBITDA for the full year of 2024 was negative $14.5 million, an improvement from negative $19.8 million in 2023 [34] - The company has amended and extended its credit facility, increasing liquidity by $4 million [43] Q&A Session Summary Question: Comments on customer budget softening - Management noted recent softening in customer budgets, particularly among smaller biotech firms, while larger pharma customers remain positive [51][52] Question: Composition of new customer pipeline - Most new customers are in preclinical or phase one stages, with successful transitions from phase two customers [56] Question: Any large one-time orders expected in 2025 - Management indicated no significant one-time orders are anticipated for 2024, but acknowledged potential revenue lumpiness [58][61] Question: Updated number of cell and gene therapy customers - The company now supports over 100 total cell and gene therapy customers, with 27% of total revenue coming from this segment [66] Question: Revenue phasing for 2025 - Management expects Q1 2025 to be the lowest quarter, with a gradual increase through Q2 and Q3, followed by a potential decrease in Q4 [70] Question: Revenue ramp for new clinical customers - It typically takes about a year to a year and a half for new clinical customers to reach spending levels comparable to more mature customers [79] Question: Pricing changes for reagents - The company implemented mid-single-digit price increases for its products at the beginning of the year [82]

Core Viewpoint - The intrinsic value of CNOOC is composed of several components, including PV-10 value of proven reserves, discounted value of proven but unconfirmed reserves, increased value from enhanced oil recovery in old oil fields, value of exploration and extraction rights in domestic offshore areas, and net cash on the balance sheet [2][3]. Summary by Sections - Under the assumption of an average Brent crude oil price of $82 in 2023, CNOOC's PV-10 value is approximately 882.1 billion yuan, corresponding to proven reserves of about 678 million barrels. For 2024, with an average Brent price of $80, the proven reserves are estimated at 732 million barrels, with a discounted value of around 960 billion yuan [2][3]. - By the end of 2024, CNOOC's proven but unconfirmed reserves are estimated at 750 million barrels, with a barrel oil discounted value of approximately $12, leading to a total discounted value of about 640 billion yuan [3]. - The increased value from enhanced oil recovery in old oil fields is estimated at around 150 billion yuan. CNOOC discovers approximately 100 million barrels of new oil and gas reserves annually, adding about 71 billion yuan in value each year. The value of CNOOC's exploration rights in domestic oil and gas blocks is estimated at around 300 billion yuan [3]. - CNOOC's net cash is projected to be around 150 billion yuan by the end of 2024. The total discounted value of CNOOC is calculated to be approximately 2.2 trillion yuan, which, when applying a 30% discount, results in a value of about 1.54 trillion yuan [3]. - If the average Brent crude oil price hypothetically drops to $70, CNOOC's average annual profit over the next ten years is expected to decline by about 28 billion yuan, leading to a total discounted value reduction of approximately 250 billion yuan, bringing the total discounted value down to about 1.365 trillion yuan after applying the 30% discount [3][4]. - Currently, CNOOC's H-share market capitalization is around 773 billion yuan. The company has committed to a dividend payout ratio of no less than 45% of its annual profits over the next three years, indicating a strong intention to return value to shareholders [4].

Group 1 - The core viewpoint of the article emphasizes the significant growth of the technology sector, particularly driven by the domestic AI model DeepSeek, which has led to a surge in various tech-related stocks and ETFs in the A-share market [1][7] - The Hang Seng Technology Index ETF has seen a year-to-date increase of over 30%, indicating strong performance in the tech sector [1] - The "technology + dividend" strategy is highlighted as a favorable investment approach, combining high-growth tech assets with stable dividend-paying stocks to enhance portfolio resilience and returns [2][9] Group 2 - There is an increasing demand for high cash flow assets as China's economy transitions towards high-quality development, moving away from reliance on debt and traditional real estate [4][5] - Free cash flow (FCF) is defined as the maximum cash available for distribution to capital providers after necessary expenditures, and it is crucial for a company's survival and dividend stability [4][5][13] - The introduction of the Free Cash Flow ETF (159201) fills a gap in the market for Smart Beta tools, providing investors with a new long-term investment option in the A-share market [2][10] Group 3 - The article discusses the rising interest in dividend assets, driven by policy changes encouraging dividends, declining long-term interest rates, and increased demand from institutional investors [6][8] - Historical data shows that dividend indices have outperformed the broader market indices over the past decade, reinforcing the attractiveness of dividend-paying stocks [5][8] - The Free Cash Flow Index has been designed to select high-quality companies with stable cash flows, enhancing the investment strategy's effectiveness [12][14]

Group 1: Personal Income Tax Regulations - The National Taxation Administration announced new regulations for personal income tax reconciliation, emphasizing the protection of taxpayers' rights and clearer definitions of responsibilities [1][2] - The new regulations allow taxpayers to handle reconciliation through the personal income tax app from March 1 to March 20, 2024, with a focus on providing better legal protection for taxpayers [1] - The reform of the personal income tax system has shifted from a classification-based approach to a combined approach, allowing for more flexible tax policies [1] Group 2: Fiscal Technology Expenditure Rankings - Zhejiang province surpassed Guangdong to rank first in fiscal technology expenditure for 2024, with expenditures of 887 billion yuan and 884 billion yuan respectively [3] - The top ten provinces showed varying growth rates in technology spending, with some provinces like Hubei and Zhejiang maintaining double-digit growth [3][4] - The emphasis on innovation and increased fiscal technology spending reflects a broader trend of prioritizing foundational research and key sectors [3][4] Group 3: Real Estate Market in Tianjin - Tianjin's recent land auction set a new record for floor prices, with a notable plot in the Heping District selling for 43,449 yuan per square meter, marking an 8.82% premium [5][6] - The auction included seven residential plots, all sold, indicating a stable performance in the land market despite varying demand levels [6] - The market is seeing a shift towards high-quality residential developments, with developers being cautious due to financial pressures [6] Group 4: Nvidia's Financial Performance - Nvidia reported a 78% year-over-year increase in revenue for Q4 of fiscal year 2025, reaching 39.3 billion USD, exceeding analyst expectations [7] - The company anticipates Q1 revenue between 42.14 billion and 43.86 billion USD, driven by strong demand for AI chips [7][8] - Despite a slight decline in gaming revenue, Nvidia's overall performance remains robust due to new product launches and a growing AI infrastructure market [7][8] Group 5: DeepSeek's Pricing Strategy - DeepSeek announced significant price reductions for its API services during off-peak hours, aiming to attract more enterprise users [9][10] - The company is also accelerating the release of its R2 model, which is expected to enhance its competitive edge in the AI market [9][10] - DeepSeek's pricing strategy reflects a shift towards maintaining market share amid increasing competition from other AI service providers [9][10] Group 6: Mercedes-Benz's Market Strategy in China - Mercedes-Benz is launching a major product offensive in China, planning to introduce seven new models to regain market share amid declining sales [11][12] - The company reported a slight decrease in overall sales and a significant drop in electric vehicle sales, highlighting challenges in the transition to electric mobility [11][12] - To address competitive pressures, Mercedes-Benz is intensifying its localization strategy and increasing investments in R&D and production in China [12] Group 7: Growth of Free Cash Flow ETFs - Several asset management firms have submitted applications for free cash flow ETFs, indicating growing investor interest in this investment vehicle [13][14] - Free cash flow is a key indicator of a company's financial health, and these ETFs aim to reflect the performance of financially stable companies [13] - The rise of free cash flow ETFs aligns with a broader trend of investors seeking conservative investment options in the stock market [14]

首批自由现金流主题ETF来了！ 2月27日，国泰基金旗下新品现金流ETF(159399)正式登陆深交所上市交易。该产品募集资金14.31亿元，有效 认购户数达1.49万户。个人投资者持有的基金份额占基金总份额的95.81%，显示了投资者对于现金流ETF的认 可。 作为一款定位"红利替代"的创新工具，该ETF聚焦高自由现金流企业，凭借其大中市值风格、月月评估分红的 机制，以及政策与基本面双重驱动的投资逻辑，引发市场高度关注。 业内人士表示，现金流ETF的上市，不仅为投资者提供了红利策略的升级选择，更标志着A股被动投资工具进 一步向精细化、策略化演进。在政策与基本面双轮驱动下，"现金牛"行情或成为2025年市场主线之一，而该产 品凭借清晰的定位与强大的管理能力，有望成为资金配置的重要载体。 聚焦"现金奶牛"，锚定高质量企业红利替代价值 1月10日，国内首批自由现金流ETF正式获批。2月20日，国泰基金发布公告称，旗下国泰富时中国A股自由现 金流聚焦ETF于2月19日成立，募集资金14.31亿元，有效认购户数达1.49万户。2月27日，该ETF正式登陆深交 所上市交易。 据悉，自由现金流是指企业在支付了所有必要的经 ...

Financial Data and Key Metrics Changes - In 2024, Group revenue increased by 6.7% to $8.5 billion, and adjusted EBITDA also increased by 6.7% to $392 million, exceeding adjusted EBITDA guidance by $12 million [11][7][10] - Adjusted net income for the full year was $120.9 million, with adjusted diluted EPS increasing by 2.4% to $1.27 per share [11][27] - Net debt at the end of 2024 was $637 million, with net leverage at 1.6 times, indicating a strong financial position [12][10] Business Line Data and Key Metrics Changes - Fresh Fruit segment delivered adjusted EBITDA of $214.8 million for the full year, an increase of $5.9 million compared to 2023, driven by volume growth in bananas and plantains [12][13] - Diversified EMEA segment achieved adjusted EBITDA of $131.5 million for the full year, with a like-for-like revenue growth of 4.4% [16][17] - Diversified Fresh Produce Americas segment reported a like-for-like revenue increase of 16.1%, with adjusted EBITDA increasing by 52.3% for the full year [32][33] Market Data and Key Metrics Changes - North America saw good volume growth in bananas and plantains, while the European market experienced high volumes in bananas and lower shipping costs [13][14] - The EMEA segment faced headwinds due to supply challenges and weather events, but anticipates continued revenue growth in 2025 [17][16] - The Fresh Vegetables business showed positive cash flow for the full year, indicating a turnaround despite accounting adjustments [21] Company Strategy and Development Direction - The company is focused on capital allocation and managing invested capital, with strategic investments in expanding shipping capacity and improving operational performance [8][10] - There is an ongoing process to determine the best strategic alternative for the vegetables business, which remains a priority [20][21] - The company plans to maintain a baseline level of capital expenditure in line with depreciation expenses, while exploring development opportunities for future growth [41][70] Management Comments on Operating Environment and Future Outlook - Management acknowledged challenges in 2025, including the impact of Tropical Storm Sara and geopolitical uncertainties affecting sourcing costs and supply chains [40][41] - The company aims for adjusted EBITDA in the range of $370 million to $380 million for 2025, reflecting a more normalized year compared to 2024 [41][38] - Management remains optimistic about the underlying fundamentals of the business and is focused on navigating challenges while capitalizing on growth opportunities [15][38] Other Important Information - The company declared a dividend of $0.08 for the fourth quarter, to be paid on April 3, 2025 [37] - Free cash flow from continuing operations was $180.3 million for the full year, benefiting from strong adjusted EBITDA performance [36] Q&A Session Summary Question: Can you unpack the EBITDA guidance for 2025? - Management indicated that the guidance reflects known headwinds, including the impact from Tropical Storm Sara and macroeconomic uncertainties, with expectations for a slower start to the year [45][49][54] Question: What mitigation strategies are in place regarding potential tariffs? - Management believes that the demand for fresh produce will remain strong, and they are prepared to adjust pricing and sourcing strategies if tariffs are implemented [56][58][60] Question: What is the focus on capital allocation moving forward? - The company is prioritizing leveraging while also considering targeted M&A opportunities, with ongoing internal development projects aimed at enhancing growth [65][70][72] Question: What are the expectations for the Diversified EMEA segment? - Management noted that while there are some profit weaknesses in certain regions, they see more opportunities than challenges and expect continued growth [75][76] Question: Is there a risk of elasticity in pricing for high-value products like avocados? - Management expressed confidence that the U.S. market will continue to demand these products, despite potential tariff impacts, due to limited domestic production capabilities [78][80]

今天港股继续暴涨，恒生科技下午三点半一度突破了6000点，虽然在6000点以上只待了短短三分钟左右，但好歹也是 2022年以来，恒生科技首 次重返6000点 ，不禁让人想到渣渣辉的那句经典台词，"三年了，你知道我这三年怎么过的吗？" 从目前的位置看，我们昨晚说的结论不变，如果是底仓的话，建议还是 港股红利+港股科技 的组合，至少从动态PE看，恒指和恒科的估值还在 历史中位数附近，有一定的安全边际。 ...... 今天A股继续被港股带飞，全面上涨。 最近A股确实要感谢港股，要不是港股的坚挺表现，其实A股很多概念板块看起来，已经快炒不动了。 比如 Deepseek概念 ，已经震荡了一周多，没有往上了； 又比如， 机器人板块 ，明眼人都知道估值已经飞上天了，按照阿指导的说法： " 大量声称做丝杠、减速器的汽车零部件公司，被炒到 150 亿甚至 200 亿后， 硬件的狂欢可能到了一个顶部，因为机器人未来三年的量，都无法 支撑起现在硬件的估值了。 " 而部分蹭机器人概念的董秘，狂发朋友圈，那种恨不得把公司卖给你的样子，实在太典了。 昨晚我们表达了对港股的几层核心观点，今天帮大家正好同步印证一下，因为 今天一早， UBS ...